Literature DB >> 22127952

Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults.

Eamonn M M Quigley1.   

Abstract

For decades, if not centuries, a variety of products with what would now be regarded as prebiotic and probiotic properties have been consumed by the general public and advocated for their benefits on health and, in particular, gastrointestinal well-being. More recently, medical science has taken a great interest in the population of micro-organisms, the gut microbiota that normally populates the human gut, and the range of important functions carried out by the microbiota in health is being progressively defined. As a corollary, the list of disorders and diseases that may result from disruption of the normal microbiota and/or its interaction with the host continues to grow. A scientific basis for the use of probiotics and prebiotics is, therefore, beginning to emerge. Unfortunately, although progress has been made, the clinical evidence to support the use of these preparations lags behind. Nevertheless, a number of human disease states may benefit from the use of probiotics, most notably, diarrheal illnesses, some inflammatory bowel diseases, certain infectious disorders, and irritable bowel syndrome. Prebiotics promote the growth of "good" bacteria, and although a variety of health benefits have been attributed to their use, prebiotics have been subjected to few large-scale clinical trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127952     DOI: 10.1177/0884533611423926

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  18 in total

Review 1.  Probiotics for the treatment of inflammatory bowel disease.

Authors:  Ganesh R Veerappan; John Betteridge; Patrick E Young
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 2.  Minireview: Gut microbiota: the neglected endocrine organ.

Authors:  Gerard Clarke; Roman M Stilling; Paul J Kennedy; Catherine Stanton; John F Cryan; Timothy G Dinan
Journal:  Mol Endocrinol       Date:  2014-06-03

3.  Probiotic Bifidobacterium species stimulate human SLC26A3 gene function and expression in intestinal epithelial cells.

Authors:  Anoop Kumar; Cameron Hecht; Shubha Priyamvada; Arivarasu N Anbazhagan; Anas Alakkam; Alip Borthakur; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja
Journal:  Am J Physiol Cell Physiol       Date:  2014-08-20       Impact factor: 4.249

Review 4.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

5.  Lactobacillus acidophilus stimulates intestinal P-glycoprotein expression via a c-Fos/c-Jun-dependent mechanism in intestinal epithelial cells.

Authors:  Shubha Priyamvada; Arivarasu N Anbazhagan; Anoop Kumar; Vikas Soni; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja; Seema Saksena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-02-11       Impact factor: 4.052

6.  Prevention of Heat Stress Adverse Effects in Rats by Bacillus subtilis Strain.

Authors:  Iryna Sorokulova; Ludmila Globa; Oleg Pustovyy; Vitaly Vodyanoy
Journal:  J Vis Exp       Date:  2016-07-11       Impact factor: 1.355

Review 7.  Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.

Authors:  Rok Orel; Tina Kamhi Trop
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 8.  Acute Radiation Syndrome and the Microbiome: Impact and Review.

Authors:  Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

Review 9.  Systemic effects of gut microbiota and its relationship with disease and modulation.

Authors:  Jolie T K Ho; Godfrey C F Chan; James C B Li
Journal:  BMC Immunol       Date:  2015-03-26       Impact factor: 3.615

10.  Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients.

Authors:  Ranganathan Natarajan; Bohdan Pechenyak; Usha Vyas; Pari Ranganathan; Alan Weinberg; Peter Liang; Mary C Mallappallil; Allen J Norin; Eli A Friedman; Subodh J Saggi
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.